MYNZ (Mainz Biomed NV) Construction In Progress : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mainz Biomed NV Construction In Progress?

Mainz Biomed NV's quarterly construction in progress declined from Dec. 2023 ($0.06 Mil) to Jun. 2024 ($0.05 Mil) and declined from Jun. 2024 ($0.05 Mil) to Dec. 2024 ($0.00 Mil).

Mainz Biomed NV's annual construction in progress increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.06 Mil) but then declined from Dec. 2023 ($0.06 Mil) to Dec. 2024 ($0.00 Mil).

Mainz Biomed NV Construction In Progress Historical Data

The historical data trend for Mainz Biomed NV's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mainz Biomed NV Construction In Progress Chart

Mainz Biomed NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Construction In Progress

Get a 7-Day Free Trial

0.06

Mainz Biomed NV Quarterly Data
	Dec19	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Dec24
Construction In Progress	Get a 7-Day Free Trial									0.05	0.05	0.06	0.05	-

Mainz Biomed NV Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Mainz Biomed NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mainz Biomed NV (NAS:MYNZ) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

Robert Koch Strasse 50, Sirius Gutenberg Park, Mainz, RP, DEU, 55129

Website

https://www.mainzbiomed.com

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.